Discontinued — last reported Q4 '25
Tax
Deferred Tax
Vertex Pharmaceuticals Deferred Tax remained flat by 0.0% to -$127.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 46.4%, from -$87.20M to -$127.70M. Over 2 years (FY 2023 to FY 2025), Deferred Tax shows relatively stable performance with a -2.4% CAGR.
Analysis
StatementIncome Statement
SectionTax
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
A large deferred tax benefit may indicate future tax liabilities, while a large expense may suggest future tax savings.
Detailed definition
This metric represents the portion of income tax expense that is deferred to future periods due to temporary differences...
Peer comparison
Standard accounting line item found in the tax reconciliation section of the income statement for most public companies.
Metric ID:
msft_deferred_income_tax_expense_benefitHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$536.50M | -$348.80M | -$510.80M |
| YoY Change | — | +35.0% | -46.4% |
Range-$536.50M – -$348.80M
CAGR-2.4%
Avg YoY Growth-5.7%
Median YoY Growth-5.7%
Deferred Tax at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred tax?
- Vertex Pharmaceuticals (VRTX) reported deferred tax of -$127.70M in Q4 2025.
- How has Vertex Pharmaceuticals's deferred tax changed year-over-year?
- Vertex Pharmaceuticals's deferred tax decreased by 46.4% year-over-year, from -$87.20M to -$127.70M.
- What is the long-term trend for Vertex Pharmaceuticals's deferred tax?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's deferred tax has grown at a -2.4% compound annual growth rate (CAGR), from -$536.50M to -$510.80M.
- What does deferred tax mean?
- The portion of tax expense that is not currently payable but will be settled in future periods.